Media stories about Microbot Medical (NASDAQ:MBOT) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Microbot Medical earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 43.8465315374629 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Microbot Medical (MBOT) traded down 0.811% on Wednesday, reaching $1.101. The company’s stock had a trading volume of 94,620 shares. Microbot Medical has a 12-month low of $1.00 and a 12-month high of $15.66. The company’s market capitalization is $48.49 million. The firm has a 50-day moving average of $1.22 and a 200 day moving average of $2.06.
Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.44. On average, equities research analysts anticipate that Microbot Medical will post ($25.02) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Microbot Medical (MBOT) Stock Price” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.com-unik.info/2017/11/01/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-microbot-medical-mbot-stock-price.html.
In other Microbot Medical news, Director Moshe Shoham sold 33,700 shares of the business’s stock in a transaction on Monday, October 9th. The stock was sold at an average price of $1.50, for a total transaction of $50,550.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Yoseph Bornstein sold 50,000 shares of the business’s stock in a transaction on Tuesday, September 19th. The stock was sold at an average price of $1.18, for a total value of $59,000.00. The disclosure for this sale can be found here. Insiders have sold 424,310 shares of company stock worth $520,396 in the last three months. 31.83% of the stock is currently owned by corporate insiders.
Microbot Medical Company Profile
Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.
What are top analysts saying about Microbot Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Microbot Medical Inc. and related companies.